(Total Views: 508)
Posted On: 02/02/2021 3:40:23 PM
Post# of 153940
there should be a relatively short period for trials, start to finish, as compared to other therapeutics.
Read More: https://investorshangout.com/post/view?id=603...z6lLZ5jx7c
That is such an important observation in regards to CYDY. Once efficacy has been demonstrated the route to and through any and all future phase three trials, in any indication, will be shortened dramatically.as will the CYDY road to full scale pharma size and triple digit stock price..Leronlimab's aspirin like safety profile is a tremendous advantage. It is almost assured there will be no severe adverse effects in any future phase 2 or 3 CYDY trials. As a practical matter that means all future CYDY phase 3 trials will be be practically binary in nature.
CYDY is in the lead and rounding the far turn. Come on CYDY. GLTA.
Read More: https://investorshangout.com/post/view?id=603...z6lLZ5jx7c
That is such an important observation in regards to CYDY. Once efficacy has been demonstrated the route to and through any and all future phase three trials, in any indication, will be shortened dramatically.as will the CYDY road to full scale pharma size and triple digit stock price..Leronlimab's aspirin like safety profile is a tremendous advantage. It is almost assured there will be no severe adverse effects in any future phase 2 or 3 CYDY trials. As a practical matter that means all future CYDY phase 3 trials will be be practically binary in nature.
CYDY is in the lead and rounding the far turn. Come on CYDY. GLTA.
(4)
(0)
